Is Biogen (BIIB) a risky stock?
As of July 21, 2026, Clavix grades Biogen (BIIB) B+ for risk, a composite score of 76 out of 100 on an A+ to F scale, which puts BIIB in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind BIIB's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how BIIB scores on each, as of July 21, 2026.
What's moving BIIB's risk right now
Company-specific signals Clavix flags behind BIIB's current grade, drawn from recent news and filings as of July 21, 2026.
The data supports the strategic direction of Biogen's Alzheimer's pipeline and its Ionis partnership, but near-term readouts from Denali, Eisai, and Lilly in the anti-tau space co…
The encouraging Phase 2 readout for diranersen supports Biogen's Alzheimer's pipeline diversification beyond Leqembi, potentially positioning the company for a meaningful new grow…
Biogen is positioning its SMA franchise (Spinraza) within a treatment paradigm that emphasizes longer-term patient optimization, suggesting sustained demand beyond initial life-sa…
What a B+ grade means
On the Clavix A+ to F scale, BIIB's composite of 76 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell BIIB or any security. Grades are risk indicators, not predictions of return. Data may be delayed.